Valneva (Nasdaq: VALN) to meet investors at J.P. Morgan conference 2026

Rhea-AI Filing Summary

Valneva SE filed a Form 6-K to furnish a press release announcing that its management will meet investors during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–14, 2026. The company plans one-on-one meetings with existing shareholders and discussions with other institutional specialist investors.

CEO Thomas Lingelbach and CFO Peter Bühler will present upcoming catalysts from Valneva’s clinical pipeline, including a pivotal data readout for its Lyme disease vaccine in the first half of the year, and will also discuss its commercial vaccine portfolio. Valneva describes itself as a specialty vaccine company with three proprietary travel vaccines on the market and a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a tetravalent Shigella vaccine candidate.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: January 9, 2026

Commission File Number: 001-40377

Valneva SE

(Translation of registrant's name into English)

6 rue Alain Bombard

44800 Saint-Herblain, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On January 9, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K is hereby incorporated by reference into the registrant's registration Statement on Form F-3 (File No. 333-268071).

Exhibit
Exhibit 99.1			Press release dated January 9, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE (Registrant)

Date: January 9, 2026

/s/ Thomas Lingelbach

Thomas Lingelbach

Chief Executive Officer and President

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, January 12-14, 2026, in San Francisco.

Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss upcoming catalysts from its clinical development pipeline, including the pivotal data readout for its Lyme disease vaccine in the first half of this year, as well as the Company’s commercial portfolio of vaccines.

To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at investors@valneva.com.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelot-fontaine@valneva.com     Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, to regulatory approval of product candidates and review of existing products, and financial guidance including projected product sales, total revenue and total R&D investments. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or

developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

FAQ

What did Valneva (VALN) announce in this Form 6-K?

Valneva SE announced that members of its management team will meet one-on-one with existing shareholders and other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

When and where will Valneva meet investors during the J.P. Morgan Healthcare Conference?

Valneva plans investor meetings at the 44th Annual J.P. Morgan Healthcare Conference, which takes place January 12–14, 2026, in San Francisco.

Which Valneva executives will attend the J.P. Morgan Healthcare Conference?

Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will meet investors and discuss the company’s clinical development pipeline and commercial vaccine portfolio.

What upcoming catalysts will Valneva discuss with investors?

Valneva plans to discuss upcoming catalysts from its clinical pipeline, including the pivotal data readout for its Lyme disease vaccine in the first half of the year, along with developments across its commercial vaccine portfolio.

How can institutional investors schedule a meeting with Valneva at the conference?

Institutional investors and analysts can schedule a one-on-one investor meeting with Valneva by contacting the investor relations department at investors@valneva.com.

What type of company is Valneva and what products does it have?

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. It currently markets three proprietary travel vaccines and is advancing a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a tetravalent Shigella vaccine candidate.

How is this Form 6-K related to Valneva’s other SEC filings?

The information contained in this Form 6-K, including the attached press release, is incorporated by reference into Valneva’s registration statement on Form F-3 with file number 333-268071.